Quest Diagnostics Inc
corporate_fare Company Profile
Quest Diagnostics Inc (NYSE:DGX) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 12 items for DGX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-07-23, rated 8/10. Across its 12 most recent items scored 7 or higher, the top rating is 8/10, with 3 rated 8 or above. Recent SEC coverage for DGX spans 10-Q, 8-K, FWP, 10-K.
Recent high-impact activity:
- Quest Diagnostics Lifts FY EPS View as Q2 Revenue Tops $3.04B
- Quest Diagnostics Lifts Full-Year Outlook on Strong Q2 Beat
- Quest Diagnostics Guides FY Adj EPS $11.05-$11.25, Above Consensus
- Quest Diagnostics' Haystack MRD Test Gains Nationwide Approval with Key New York State Nod
- Quest Diagnostics Issues $500M in 5.000% Senior Notes Due 2036, Finalizing Recent Offering
Financial Snapshot
Short Interest & Short Volume
3.69 days to coverFINRA reported short interest of 3,600,559 shares in DGX as of the September 15, 2026 settlement, a 4.5% increase from the prior period — about 3.7 days to cover at its recent average daily volume. On October 2, 2026, 35.1% of DGX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for DGX, detected from its recent SEC filings · based on capital-structure filings through 2026-04-27.
Finalized Debt Offering · Maturity and Yield
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →